XAGE - Carmell Therapeutics Corporation Earnings per share for the last twelve months

The trailing 12-month EPS for Longevity Health Holdings reflects a trend where the -8.57 mark serves as the current indicator. The delivery of aesthetic products relies on pharmaceutical-grade specialized transport. Growth is driven by B2B deals, e-commerce expansion, and the implementation of a plasma biomaterials platform. Diversified hubs and long-term agreements ensure the stability of dermatological product supplies.
Analytical breakdowns for Longevity Health Holdings

Longevity Health Holdings (XAGE) competes in the biomedical aesthetics niche, where success depends on the implementation of plasma product lines. This indicator measures the rolling annual profit, neutralizing the impact of share issuance to assess the real yield per share. Investors are weighing this result against high marketing costs and limited liquidity reserves. By analyzing the specific net income over the last 12 months, one can identify dangerous price extremes. The price action on this chart helps avoid purchasing the asset at the peak of fundamental overvaluation.